2-(2-mercaptoethyl)benzoic acid | 378242-69-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2-mercaptoethyl)benzoic acid
• 英文别名: 2-(2-mercaptoethyl)-benzoic acid；2-(2-sulfanylethyl)benzoic acid
• CAS: 378242-69-4
• 化学式: C₉H₁₀O₂S
• 分子量: 182.243
• InChiKey: OYNMQTZKBJYUNY-UHFFFAOYSA-N

物化性质

• 沸点：
  333.8±25.0 °C(Predicted)
• 密度：
  1.224±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  38.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-乙烯基苯甲酸 在 偶氮二异丁腈 、 potassium carbonate 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 水 、 丙酮 、 甲苯 为溶剂， 反应 26.41h， 生成 2-(2-mercaptoethyl)benzoic acid
  参考文献：
  名称：

  Design, Synthesis, and Pharmacological Evaluation of Glutamate Carboxypeptidase II (GCPII) Inhibitors Based on Thioalkylbenzoic Acid Scaffolds

  摘要：

  A series of thiol-based glutamate carboxypeptidase II (GCPII) inhibitors have been synthesized with either a 3-(mercaptomethyl)benzoic acid or 2-(2-mercaptoethyl)benzoic acid scaffold. Potent inhibitors were identified from each of the two scaffolds with IC50 values in the single-digit nanomolar range, including 2-(3-carboxybenzyloxy)-5-(mercaptomethyl)benzoic acid 27c and 3-(2-mercaptoethyl)-biphenyl-2,3'-dicarboxylic acid 35c. Compound 35c was found to be metabolically stable and selective over a number of targets related to glutamate-mediated neurotransmission. Furthermore, compound 35c was found to be orally available in rats and exhibited efficacy in an animal model of neuropathic pain following oral administration.

  DOI：

  10.1021/jm300488m

文献信息

• Naaladase inhibitors for treating retinal disorders and glaucoma
  申请人：——

  公开号：US20030036534A1

  公开（公告）日：2003-02-20

  The present invention relates to pharmaceutical compositions and methods for treating a retinal disorder or glaucoma using NAALADase inhibitors.

  本发明涉及使用NAALADase抑制剂治疗视网膜疾病或青光眼的药物组合物和方法。
• Thiolalkyl benzoic acid derivatives
  申请人：——

  公开号：US20030100607A1

  公开（公告）日：2003-05-29

  The present invention relates to new thiolalkyl benzoic acids, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, effecting neuronal activity, effecting TGF-&bgr; activity, inhibiting angiogenesis, and treating glutamate abnormalities, neuropathy, pain, compulsive disorders, prostate diseases, cancers, glaucoma, retinal disorders, and cancer.

  本发明涉及新的硫代烷基苯甲酸，包含这些化合物的药物组合物和诊断试剂盒，以及使用这些化合物抑制NAALADase酶活性、检测NAALADase水平发生变化的疾病、影响神经元活性、影响TGF-β活性、抑制血管生成以及治疗谷氨酸异常、神经病、疼痛、强迫症、前列腺疾病、癌症、青光眼、视网膜疾病和癌症的方法。
• Naaladase inhibitors for treating opioid tolerance
  申请人：Guilford Pharmaceuticals Inc.

  公开号：US20040186081A1

  公开（公告）日：2004-09-23

  The present invention relates to pharmaceutical compositions and methods for treating opioid tolerance using NAALADase inhibitors.

  本发明涉及制药组合物和使用NAALADase抑制剂治疗阿片类药物耐受性的方法。
• NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA
  申请人：GUILFORD PHARMACEUTICALS INC.

  公开号：EP1292601A2

  公开（公告）日：2003-03-19
• THIOLALKYL BENZOIC ACID DERIVATIVES
  申请人：GUILFORD PHARMACEUTICALS INC.

  公开号：EP1406867A2

  公开（公告）日：2004-04-14